Carregant...
The combination of histone deacetylase inhibitors with immune-stimulating antibodies has potent anti-cancer effects
The use of immunotherapy to treat cancer is rapidly gaining momentum. Using pre-clinical mouse models, we have recently demonstrated potent and long lasting tumor regression can be elicited by immune-stimulating monoclonal antibodies (mAbs) when combined with histone deacetylase inhibitors (HDACi) a...
Guardat en:
| Autors principals: | , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Landes Bioscience
2012
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3382866/ https://ncbi.nlm.nih.gov/pubmed/22737621 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/onci.18804 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|